X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AUROBINDO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AUROBINDO PHARMA FRESENIUS KABI ONCO./
AUROBINDO PHARMA
 
P/E (TTM) x 22.1 16.0 138.2% View Chart
P/BV x 3.1 4.1 75.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   AUROBINDO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA
Mar-17
FRESENIUS KABI ONCO./
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs176895 19.7%   
Low Rs79622 12.6%   
Sales per share (Unadj.) Rs37.7254.6 14.8%  
Earnings per share (Unadj.) Rs5.139.3 13.0%  
Cash flow per share (Unadj.) Rs6.746.6 14.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs42.5160.0 26.6%  
Shares outstanding (eoy) m158.23585.88 27.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.3%   
Avg P/E ratio x25.019.3 129.4%  
P/CF ratio (eoy) x18.916.3 116.2%  
Price / Book Value ratio x3.04.7 63.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m20,135444,390 4.5%   
No. of employees `0001.214.0 8.2%   
Total wages/salary Rs m70317,678 4.0%   
Avg. sales/employee Rs Th5,176.210,667.8 48.5%   
Avg. wages/employee Rs Th610.41,264.3 48.3%   
Avg. net profit/employee Rs Th699.61,645.8 42.5%   
INCOME DATA
Net Sales Rs m5,963149,157 4.0%  
Other income Rs m181,159 1.6%   
Total revenues Rs m5,981150,316 4.0%   
Gross profit Rs m1,43034,343 4.2%  
Depreciation Rs m2584,276 6.0%   
Interest Rs m-26667 -3.9%   
Profit before tax Rs m1,21630,558 4.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3427,597 4.5%   
Profit after tax Rs m80623,012 3.5%  
Gross profit margin %24.023.0 104.2%  
Effective tax rate %28.124.9 113.2%   
Net profit margin %13.515.4 87.6%  
BALANCE SHEET DATA
Current assets Rs m5,10292,062 5.5%   
Current liabilities Rs m2,38566,223 3.6%   
Net working cap to sales %45.617.3 262.9%  
Current ratio x2.11.4 153.8%  
Inventory Days Days150106 141.6%  
Debtors Days Days11368 167.4%  
Net fixed assets Rs m5,14862,919 8.2%   
Share capital Rs m158586 27.0%   
"Free" reserves Rs m6,55693,133 7.0%   
Net worth Rs m6,73293,719 7.2%   
Long term debt Rs m9521,814 52.5%   
Total assets Rs m10,388162,494 6.4%  
Interest coverage x-45.846.8 -97.8%   
Debt to equity ratio x0.10 730.8%  
Sales to assets ratio x0.60.9 62.5%   
Return on assets %7.514.6 51.5%  
Return on equity %12.024.6 48.8%  
Return on capital %14.632.7 44.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29875,838 7.0%   
Fx outflow Rs m1,77230,224 5.9%   
Net fx Rs m3,52545,613 7.7%   
CASH FLOW
From Operations Rs m1,27432,786 3.9%  
From Investments Rs m-1,204-17,870 6.7%  
From Financial Activity Rs m-196-19,153 1.0%  
Net Cashflow Rs m-126-4,239 3.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 9.6 27.7 34.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   42,599 69,601 61.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS